secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001104659-25-003026
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics reports 65% ORR in Ph1 combo zelenectide plus pembro in 1L mUC; outlines 2025 milestones
--------------------------------------------------------------------------------

- Updated Phase 1 Duravelo-1 data: 65% ORR (13/20 evaluable) in 1L cisplatin-ineligible mUC; 50% confirmed ORR.
- Median duration of response not yet mature; 12 patients remain on treatment at data cut-off (Jan 3, 2025).
- No Grade 4/5 TRAEs of clinical interest; no patients withdrew due to zelenectide TRAEs; low-grade peripheral neuropathy, skin/eye events.
- Cash and equivalents $890.9M as of Sept 30, 2024; financial runway into 2H 2027.
- 2025 milestones: Phase 2/3 Duravelo-2 dose selection data in 2H; initiate Phase 1 trials in NECTIN4-amplified breast, lung, and multi-tumor cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465925003026/0001104659-25-003026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465925003026/tm253122d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-003026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer